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Introduction
Over the last two decades, there has been an
impressive growth of experimental and clinical evidence
defining a role for the renin-angiotensin system (RAS) in
the development of ischemic cardiovascular disease. It is
now widely appreciated that activation of the RAS is
associated with a vascular toxicity that is independent of
its effects on blood pressure. This association predicted
the cardiovascular risk among treated hypertensive
patients. A long-term prospective trial by Alderman et al.
examined the relationship between the renin-sodium
profile and subsequent myocardial infarction in >1,700
patients entering a hypertension control program. After
an average of 8.3 years of follow-up, the risk of
myocardial infarction (MI) increased nearly 5-fold in
patients with a high renin-sodium profile at baseline
compared to those with a low profile, despite equivalent
success in managing hypertension (1). Another
prospective study by the same group demonstrated that
plasma renin activity (PRA), without monitoring urinary
sodium, also predicted the risk of MI in 2902
hypertensive patients during an average of 3.6 years
follow-up (2). There was, for every 2 unit increase in
PRA, an overall 25% increase in MI incidence. These
observations fueled the hypothesis that pharmacological
interruption of the RAS reduces the risk of ischemic
heart disease.
Survivors of acute myocardial infarction (AMI) are at
increased risk of fatal and non-fatal ischemic events.
Long-term survival of patients after AMI remains a major
public health objective. Important advances in secondary
prevention of AMI have been made in recent years.
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Several survival studies investigated the effects of five
different angiotensin converting enzyme (ACE) inhibitors
in more than 100.000 patients after AMI (3-10). In all
but the Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarcto Miocardica (GISSI-3) trial, double-blind,
placebo-controlled methods were used to randomize the
patients to receive either active or control treatments.
This, comprehensive investigation has revealed that ACE
inhibition on average, reduced the risk of recurrent MI by
approximately 8% per year of treatment. Recently
published follow-up study of (AIRE) trial (Randomly
Allocated Ramipril or Placebo for Heart Failure after
Acute Myocardial Infarction) provided robust evidence
that administration of ramipril to patients with clinically
defined heart failure after AMI results in a survival benefit
that is not only large (11.4% absolute reduction in
mortality), but also sustained over many years (11).
The mechanisms through which ACE inhibitors reduce
reinfarction is an active area of research. Blood pressure
reduction, reduced myocardial demand with improved
loading conditions, reduced left ventricular remodeling,
reduced sympathetic activity, reduced arterial
permeability and lipoprotein entry, growth factor
inhibition (Angiotensin II, platelet derived growth factor,
transforming growth factor β), bradykinin accumulation,
prevention of atherosclerosis, free radical scavenging, and
anti-inflammatory effects are some of the mechanisms
invoked to explain the beneficial role of ACE inhibitors. It
is likely that several of these mechanisms are operative
simultaneously. If triggering of any or all of these
mechanisms by the RAS contributes to precipitation of
infarction, interruption of the RAS by ACE inhibition
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could theoretically reduce the risk of myocardial
infarction. It is unlikely that simple improvement in left
ventricular loading conditions is the primary mechanism,
as treatment for a certain period is necessary to observe
this reduction in the incidence of acute coronary
syndromes. Recent research has demonstrated an
interesting interaction between the RAS and fibrinolytic
system (12). Accumulating data suggest that angiotensin
II (Ang II) modulates fibrinolysis (12, 13). This
interaction may be the mechanism to explain the
indisputable impact of ACE inhibitors in prevention of
myocardial infarction. In this review, we will try to define
the close relation between these two systems by
dissecting into the components of the fibrinolytic and
renin-angiotensin systems.
The fibrinolytic balance
The fibrinolytic system represents a crucial defense
mechanism against intravascular thrombosis. The
initiation of fibrinolysis is regulated by a dynamic balance
between the plasminogen activators and inhibitors in the
region of thrombus. Two major plasminogen activators
(PA) have been identified; tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (u-PA).
While both of these activators are synthesized in the
endothelium, t-PA is felt to be the primary PA in the
blood. The concentration of active t-PA is determined by
the rate of endothelial secretion, hepatic clearance and
inhibition by a specific, rapid-acting plasminogen activator
inhibitor (PAI-1). Vascular fibrinolysis is largely
modulated by the balance between t-PA and PAI-1. PAI-1
is derived from multiple sources, including the
endothelium, vascular smooth muscle cells, the liver,
adipose tissue and platelets. t-PA and PAI-1 react to form
an inactive t-PA/PAI-1 complex. Under physiological
circumstances, there is abundant supply of plasminogen in
the circulation available for activation and conversion into
plasmin. However, only small portion of plasminogen is
converted into plasmin for three reasons a) t-PA
circulates in trace concentrations in plasma, b) t-PA is
relatively inefficient PA in solution in the absence of fibrin,
and c) t-PA is inhibited by the presence of PAI-1.
Therefore, circulating levels of active t-PA, active PAI1, and t-PA/PAI-1 complex are crucial in regulation of
fibrinolysis. An imbalance between plasminogen
activators and PAI-1 can lead to clinical consequences. For
example, PAI-1 deficiency or t-PA excess can result in
abnormal bleeding (14,15), conversely, an elevated PAI-1
level is associated with myocardial infarction (16,17).
Increased plasma levels of PAI-1 have been detected in
young survivors of myocardial infarction in comparison
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with healthy age-matched controls (16). Elevated PAI-1
levels in young survivors of myocardial infarction have
also been associated with an increased risk of recurrent
infarction (17). Interestingly, there is a temporal
association between plasma PAI-1 levels which exhibit a
marked circadian variation and peak in the early morning
hours coincident with the reported peak incidence of MI
(18). Recent studies with thrombolytic agents (mainly tPA or streptokinase) in the setting of AMI have shed light
into the clinical importance of this marked circadian
variation in plasma PAI-1 levels. Becker et al. found in a
group of 28 patients that coronary artery patency 90
minutes after the beginning of treatment with t-PA was
27% between midnight and noon compared with 82%
for treatment between noon and midnight (19). These
interesting findings were confirmed in a larger study by
Kurnik (20). In this study, the onset of myocardial
infarction was confirmed to have a marked circadian
variation with a peak incidence around 10 AM. The peak
efficacy of t-PA was about 8 PM, representing a phase
difference of about 10 hours after peak infarction
incidence. Diminished efficacy of t-PA early in the day may
be explained with elevated PAI-1 levels in the morning
hours.
Experimental data also support a direct relationship
between increased levels of PAI-1 and thrombotic events.
Transgenic mice engineered to overexpress PAI-1 develop
spontaneous thrombosis (21). High concentrations of
active PAI-1 were observed in porcine coronary artery
thrombi as an important determinant of the resistance to
clot lysis by t-PA (22). Anti-PAI-1 monoclonal antibodies
accelerate fibrinolysis within the clots (23).
The renin angiotensin system and fibrinolysis
Hormonal systems like RAS have evolved as a
protector against acute fluid volume loss. In addition to
causing vasoconstriction and the retention of salt and
water, it appears that angiotensin inhibits fibrinolysis,
thereby promoting clot formation and protecting against
hemorrhage and volume loss. Activation of the reninangiotensin system (RAS) can disturb the balance of the
fibrinolytic system by stimulating excess production of
plasminogen activator inhibitor type 1 (PAI-1) and
increasing the risk of thrombotic events. Circadian
variation of these parameters support the role of
hormonal influence on fibrinolytic system (18).
Experimental and clinical studies have been designed
to define the relationship between the RAS and the
fibrinolytic system. In addition to its well-known
vasoconstrictor effects, Angiotensin II (Ang II) also
modulates fibrinolysis. Ang II stimulates PAI-1 production
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in cultured endothelial cells in a dose dependent manner
(12). Interestingly, specific Ang II receptor blockers could
not inhibit the effects of Ang II on PAI-1 production (24).
Prior work described a mechanism through which A II
may contribute to a prothrombotic state by reducing the
activity of the endogenous fibrinolytic system (25). This
investigation reported a dose-dependent increase in
plasma PAI-1 in healthy human volunteers infused with
graded doses of A II, whereas no change occurred in
control subjects given a 5% dextrose infusion. No
significant effect on t-PA concentrations resulted from A
II infusion, indicating a very selective and specific action
on PAI-1. The doses of A II used in this study simulated
plasma A II levels generated by assumption of an upright
posture. Thus, the increase in PAI-1 occurred at
physiologic levels of A II.
Another clinical study involving a subset of patients
enrolled in the SAVE study examined the relationship of
plasma t-PA-1 and PAI-1 to various neurohormones (26).
No correlation was detected between concentrations of
plasma t-PA and any of the neurohormonal parameters
measured (e.g., catecholamines, markers of the RAS,
atrial natriuretic factor, arginine, vasopressin). However,
plasma aldosterone levels and plasma renin activity both
correlated significantly with plasma PAI-1 levels (27).
Treatment with the ACE inhibitor captopril reduces
basal vascular PAI-1 expression in the normal rat aorta,
suggesting a fundamental role of angiotensin in
regulating PAI-1 expression in healthy tissues (28). Such
therapy also significantly reduces the vascular expression
of PAI-1 in rats after balloon injury to the aorta.
The beneficial effects of ACE inhibition on
fibrinolytic balance
The endothelial cell appears to regulate plasma
fibrinolytic balance by producing PAI-1 and plasminogen
activators. Via 2 parallel pathways, ACE plays a pivotal
role in maintaining the balance between PAI-1 and t-PA.
One of these pathways involves the conversion of AI to A
II, which increases expression of PAI-1. The second
pathway involves the degradation of bradykinin, an action
that inhibits production of t-PA. In the presence of active
ACE, the local increase in PAI-1 production and the
decrease in t-PA might be expected to enhance the
tendency toward thrombosis or development of
atherosclerosis.
Angiotensin I converting enzyme (ACE) inhibitors
were initially introduced as antihypertensives almost two
decades ago. In addition to their extensive use for the
treatment of arterial hypertension, ACE inhibitors have

become a huge success in the treatment of congestive
heart failure. Recently, their cardiac and vascular
protective effects have become clear. As we discussed
earlier, comprehensive investigation has revealed that
ACE inhibition reduces the risk of recurrent MI in
survivors of acute myocardial infarction. An effect of ACE
inhibition on fibrinolytic balance may contribute to the
reduction in the myocardial infarction rate achieved in
these clinical trials. This potential mechanism is supported
by the results of randomized, double-blind, placebocontrolled studies that evaluated changes in fibrinolytic
variables after ACE inhibitor therapy in patients with
myocardial infarction.
One of these studies measured t-PA antigen and PAI1 antigen and activity in 15 men who had a recent,
uncomplicated myocardial infarction. After 4 weeks of
treatment with 75 mg/day of captopril, ACE inhibition
was associated with a significant decrease in t-PA antigen
and PAI-1 activity, compared to values during placebo
administration. Although a median 18% reduction
occurred, the change in PAI-1 antigen did not reach
statistical significance (29). Jansson et al investigated
antigen and activities of t-PA and PAI-1 in 81 survivors of
myocardial infarction treated with enalapril or placebo for
3 months. ACE inhibition decreased t-PA antigen without
altering other parameters (30).
A substudy of Survival and Ventricular Enlargement
(SAVE) trial (2) demonstrated 30% higher t-PA levels in
patients randomized to captopril compared to placebo
group. Interestingly, this difference disappeared after
cessation of captopril (27).
These same fibrinolytic variables were examined in a
subset of 120 patients enrolled in the Healing and Early
Afterload Reducing Therapy (HEART) study (31). Criteria
for entry into the HEART trial were an anterior
myocardial infarction and systolic blood pressure>100
mm Hg. Patients were randomized to receive placebo,
0.625 mg/day of ramipril, or 1.25 mg/day. Basal levels of
PAI-1 activity as well as PAI-1 and t-PA antigens were
essentially identical in the 3 treatment groups, and the
PAI-1/t-PA ratio, an index of fibrinolytic balance, was
normal. After 14 days of treatment with low or high-dose
ramipril, PAI-1 activity was reduced by 22% and the PAI1 antigen level was reduced by 44%, and the t-PA antigen
levels were unchanged from baseline. Concentrations of
neither PAI-1 nor t-PA changed significantly in the
placebo group. The PAI-1/t-PA ratio increased>2-fold
with placebo administration, indicating a shift toward
thrombosis. In contrast, the normal ratio was preserved
in patients treated with ramipril. Thus, ACE inhibition
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appears to preserve the fibrinolytic balance in the
recovery phase after an acute myocardial infarction.

activity and antigen were unchanged after 4 weeks of
treatment with losartan.

In addition to activating the conversion of A I to A II,
ACE is responsible for the degradation of bradykinin, an
important mediator of t-PA production at the level of the
endothelial cell. Bradykinin therefore serves an essential
role in the regulation of fibrinolytic balance. Experimental
and clinical data support a potent stimulatory effect of
bradykinin on t-PA secretion. For example, intra-arterial
administration of bradykinin causes a dose-dependent
increase in plasma t-PA levels in rats (32). Hypertensive
human volunteers infused with graded doses of
bradykinin while receiving an ACE inhibitor have
demonstrated a striking dose-dependent increase in
plasma t-PA levels (33). In the absence of an ACE
inhibitor, however bradykinin administration had no
effect on t-PA concentrations.

Data from our laboratory support the clinical
observations of Seljeflot et al. The biologic activity of Ang
II is limited by specific enzymes that promote its
degradation. Octapeptide Ang II is cleaved to biologically
active hexapeptide Ang IV by aminopeptidases. Ang IV
binds receptors distinct from Ang II receptors. Data from
our laboratory indicate that Ang IV is the peptide that
stimulates endothelial expression of PAI-1 (24). The
induction of PAI-1 expression could be blocked by Ang IV
receptor antagonist but not Ang II receptor antagonism.
Therefore, ACE inhibitors may have superior efficacy in
reducing PAI-1 levels by blocking the generation of Ang II
and Ang IV.

Along with these clinical studies enrolling
cardiovascular patients, ACE inhibition also caused similar
effects on fibrinolytic balance in healthy subjects. In a
recent study, we examined the effect of salt depletion on
tissue-type plasminogen activator (t-PA) antigen and
plasminogen activator inhibitor-1 (PAI-1) activity and
antigen in normal subjects in the presence and absence of
ACE inhibition with quinapril 40 mg twice a day (34).
Under low (10 mmol/day) and high (200 mmol/day) salt
conditions there was significant diurnal variation in PAI-1
antigen and activity and t-PA antigen confirming previous
observations. Morning PAI-1 antigen levels were
significantly higher during low salt intake compared with
high salt intake conditions. ACE inhibition significantly
reduced 24 hour and morning PAI-1 antigen and activity
level.
Angiotensin II receptor antagonists and
fibrinolytic balance: Implications of Angiotensin II
metabolism
As we discussed earlier, experimental work suggests
that angiotensin II (Ang II) has a regulatory role on
hemostasis. Recently developed Ang II receptor blockers
interrupt renin angiotensin system by blocking the Ang II
(type I) receptor (AT1). Hence, hypothesis develops that
AT1 receptor blockers can also affect fibrinolytic balance
in a favorable way like ACE inhibitors do. Despite ample
evidence that suggests ACE inhibitors reduce PAI-1 levels,
studies assessing PAI-1 levels after blocking AT1 receptor
are in progress. Seljeflot et al. studied in vivo effects of
Ang II on fibrinolysis by treating 20 hypertensive patients
with losartan (a selective AT1 receptor antagonist) (35).
Plasma levels of t-PA activity and antigen, and PAI-1
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Conclusions
Hemostasis depends on an intricate relation between
plasma coagulation and fibrinolytic factors, blood cells,
vessel walls, extracellular matrix, blood viscosity and flow.
Circadian variation and gender differences of fibrinolytic
factors suggest an important hormonal influence in this
process. Hormonal systems such as RAS act as a
protector against acute fluid volume loss by inducing both
vasoconstriction to maintain blood pressure and the
retention of salt and water to restore normal fluid
volume. Inhibition of the fibrinolytic system by A II (or A
IV) further assists in maintaining vascular integrity by
promoting clot formation. Studies have confirmed that
these cascade of events are brought into action by RAS in
coordination and sequentially. Inappropriate activation of
the RAS may occur, however, in patients with left
ventricular dysfunction and heart failure. In such patients,
ACE-induced vasoconstriction may increase cardiac
afterload, salt and water retention may increase cardiac
preload as well as the symptoms of pulmonary congestion
and edema. Additionally, inhibition of fibrinolysis by overactivated RAS may increase the thrombotic tendency. ACE
inhibitors are indicated to counteract the vasoconstriction
and salt and water retention associated with activation of
the RAS. These drugs may also protect against
thrombosis by reducing the expression of PAI-1 normally
induced by angiotensin and by augmenting the
bradykinin-induced production of t-PA.
It remains to be seen, however, whether interruption
of renin-angiotensin cascade at other sites with AT 1
receptor blockers or renin inhibitors will have the
therapeutic success of ACE inhibitors.
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